Jessica Fye
Stock Analyst at JP Morgan
(4.12)
# 435
Out of 4,784 analysts
185
Total ratings
56.78%
Success rate
9.71%
Average return
Main Sectors:
Stocks Rated by Jessica Fye
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IONS Ionis Pharmaceuticals | Maintains: Neutral | $47 → $45 | $30.91 | +45.58% | 4 | Mar 24, 2025 | |
| ALNY Alnylam Pharmaceuticals | Upgrades: Overweight | $280 → $328 | $267.66 | +22.54% | 5 | Mar 24, 2025 | |
| MRNA Moderna | Maintains: Underweight | $40 → $33 | $31.29 | +5.48% | 12 | Mar 21, 2025 | |
| ASND Ascendis Pharma | Maintains: Overweight | $168 → $200 | $155.00 | +29.03% | 10 | Mar 18, 2025 | |
| JAZZ Jazz Pharmaceuticals | Maintains: Overweight | $200 → $209 | $124.45 | +67.95% | 4 | Feb 26, 2025 | |
| INSM Insmed | Maintains: Overweight | $83 → $92 | $76.54 | +20.20% | 7 | Feb 7, 2025 | |
| DNLI Denali Therapeutics | Maintains: Overweight | $28 → $24 | $14.07 | +70.58% | 5 | Jan 7, 2025 | |
| VRTX Vertex Pharmaceuticals | Maintains: Overweight | $503 → $500 | $496.90 | +0.62% | 7 | Dec 23, 2024 | |
| BNTX BioNTech SE | Maintains: Neutral | $124 → $122 | $94.00 | +29.79% | 10 | Nov 26, 2024 | |
| ITCI Intra-Cellular Therapies | Maintains: Overweight | $81 → $89 | $131.84 | -32.49% | 7 | Nov 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $110 → $109 | $71.87 | +51.66% | 3 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $65 → $71 | $60.44 | +17.47% | 5 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $32 → $26 | $33.21 | -21.70% | 6 | Oct 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $30 | $7.88 | +280.71% | 1 | Oct 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $52 → $57 | $62.81 | -9.26% | 11 | Sep 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $70 → $66 | $29.39 | +124.60% | 4 | Jul 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $47 → $54 | $34.21 | +57.85% | 5 | Jul 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $31 → $39 | $45.84 | -14.91% | 3 | Jun 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $280 → $300 | $305.08 | -1.67% | 14 | May 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $6 → $13 | $7.39 | +76.03% | 4 | Mar 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $15 → $17 | $18.47 | -7.96% | 3 | Mar 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Underweight | n/a | $0.76 | - | 7 | Nov 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Underweight | n/a | $4.56 | - | 2 | Nov 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Neutral | n/a | $1.54 | - | 9 | Nov 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Underweight | n/a | $0.45 | - | 6 | Nov 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Overweight | $10 | $7.75 | +29.12% | 5 | Nov 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $65 → $76 | $34.71 | +118.96% | 2 | Apr 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $204 → $240 | $5.28 | +4,443.05% | 2 | Mar 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $2.10 | - | 2 | Aug 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $22 | $1.30 | +1,592.18% | 1 | Apr 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $7 | $0.56 | +1,152.68% | 2 | Jan 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $32 → $27 | $29.07 | -7.10% | 5 | May 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $0.37 | - | 4 | Mar 11, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $7.06 | - | 3 | Feb 28, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $8.51 | - | 4 | Feb 14, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $5.73 | - | 1 | Feb 8, 2018 |
Ionis Pharmaceuticals
Mar 24, 2025
Maintains: Neutral
Price Target: $47 → $45
Current: $30.91
Upside: +45.58%
Alnylam Pharmaceuticals
Mar 24, 2025
Upgrades: Overweight
Price Target: $280 → $328
Current: $267.66
Upside: +22.54%
Moderna
Mar 21, 2025
Maintains: Underweight
Price Target: $40 → $33
Current: $31.29
Upside: +5.48%
Ascendis Pharma
Mar 18, 2025
Maintains: Overweight
Price Target: $168 → $200
Current: $155.00
Upside: +29.03%
Jazz Pharmaceuticals
Feb 26, 2025
Maintains: Overweight
Price Target: $200 → $209
Current: $124.45
Upside: +67.95%
Insmed
Feb 7, 2025
Maintains: Overweight
Price Target: $83 → $92
Current: $76.54
Upside: +20.20%
Denali Therapeutics
Jan 7, 2025
Maintains: Overweight
Price Target: $28 → $24
Current: $14.07
Upside: +70.58%
Vertex Pharmaceuticals
Dec 23, 2024
Maintains: Overweight
Price Target: $503 → $500
Current: $496.90
Upside: +0.62%
BioNTech SE
Nov 26, 2024
Maintains: Neutral
Price Target: $124 → $122
Current: $94.00
Upside: +29.79%
Intra-Cellular Therapies
Nov 4, 2024
Maintains: Overweight
Price Target: $81 → $89
Current: $131.84
Upside: -32.49%
Oct 30, 2024
Maintains: Overweight
Price Target: $110 → $109
Current: $71.87
Upside: +51.66%
Oct 30, 2024
Maintains: Neutral
Price Target: $65 → $71
Current: $60.44
Upside: +17.47%
Oct 25, 2024
Maintains: Neutral
Price Target: $32 → $26
Current: $33.21
Upside: -21.70%
Oct 8, 2024
Initiates: Overweight
Price Target: $30
Current: $7.88
Upside: +280.71%
Sep 19, 2024
Downgrades: Neutral
Price Target: $52 → $57
Current: $62.81
Upside: -9.26%
Jul 10, 2024
Maintains: Overweight
Price Target: $70 → $66
Current: $29.39
Upside: +124.60%
Jul 9, 2024
Maintains: Overweight
Price Target: $47 → $54
Current: $34.21
Upside: +57.85%
Jun 18, 2024
Maintains: Overweight
Price Target: $31 → $39
Current: $45.84
Upside: -14.91%
May 21, 2024
Maintains: Overweight
Price Target: $280 → $300
Current: $305.08
Upside: -1.67%
Mar 26, 2024
Maintains: Neutral
Price Target: $6 → $13
Current: $7.39
Upside: +76.03%
Mar 19, 2024
Maintains: Neutral
Price Target: $15 → $17
Current: $18.47
Upside: -7.96%
Nov 20, 2023
Reinstates: Underweight
Price Target: n/a
Current: $0.76
Upside: -
Nov 20, 2023
Reinstates: Underweight
Price Target: n/a
Current: $4.56
Upside: -
Nov 20, 2023
Reinstates: Neutral
Price Target: n/a
Current: $1.54
Upside: -
Nov 20, 2023
Reinstates: Underweight
Price Target: n/a
Current: $0.45
Upside: -
Nov 20, 2023
Reinstates: Overweight
Price Target: $10
Current: $7.75
Upside: +29.12%
Apr 19, 2023
Maintains: Overweight
Price Target: $65 → $76
Current: $34.71
Upside: +118.96%
Mar 8, 2022
Upgrades: Overweight
Price Target: $204 → $240
Current: $5.28
Upside: +4,443.05%
Aug 20, 2021
Downgrades: Underweight
Price Target: n/a
Current: $2.10
Upside: -
Apr 19, 2021
Initiates: Overweight
Price Target: $22
Current: $1.30
Upside: +1,592.18%
Jan 29, 2021
Upgrades: Neutral
Price Target: $7
Current: $0.56
Upside: +1,152.68%
May 12, 2020
Maintains: Overweight
Price Target: $32 → $27
Current: $29.07
Upside: -7.10%
Mar 11, 2019
Downgrades: Underweight
Price Target: n/a
Current: $0.37
Upside: -
Feb 28, 2019
Downgrades: Underweight
Price Target: n/a
Current: $7.06
Upside: -
Feb 14, 2018
Downgrades: Underweight
Price Target: n/a
Current: $8.51
Upside: -
Feb 8, 2018
Downgrades: Neutral
Price Target: n/a
Current: $5.73
Upside: -